UBS AG reaffirmed their buy rating on shares of AveXis, Inc. (NASDAQ:AVXS) in a report published on Tuesday, www.flashratings.com reports. UBS AG currently has a $122.00 price target on the stock, up from their prior price target of $95.00.

Other research analysts have also issued reports about the stock. Jefferies Group LLC reiterated a buy rating and set a $108.00 price target (up from $92.00) on shares of AveXis in a research note on Friday, August 11th. Chardan Capital reiterated a buy rating and set a $130.00 price target (up from $102.50) on shares of AveXis in a research note on Friday, August 11th. BMO Capital Markets reiterated a buy rating and set a $123.00 price target on shares of AveXis in a research note on Friday, August 11th. Citigroup Inc. set a $100.00 price target on shares of AveXis and gave the stock a buy rating in a research note on Thursday, June 15th. Finally, Zacks Investment Research upgraded shares of AveXis from a sell rating to a hold rating in a research note on Thursday, July 13th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $106.31.

AveXis (NASDAQ:AVXS) traded up 5.14% during midday trading on Tuesday, hitting $103.71. 345,014 shares of the stock traded hands. AveXis has a one year low of $43.06 and a one year high of $104.53. The company’s market cap is $3.31 billion. The company’s 50 day moving average is $93.99 and its 200-day moving average is $82.65.

AveXis (NASDAQ:AVXS) last posted its quarterly earnings data on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.10). During the same quarter in the prior year, the business posted ($0.68) EPS. On average, equities research analysts forecast that AveXis will post ($6.23) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/ubs-ag-reaffirms-buy-rating-for-avexis-inc-avxs/1615135.html.

In related news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction dated Friday, September 1st. The shares were sold at an average price of $93.25, for a total transaction of $165,985.00. Following the sale, the vice president now owns 1,780 shares of the company’s stock, valued at $165,985. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last three months, insiders have sold 5,340 shares of company stock worth $501,996. 18.60% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors boosted its holdings in AveXis by 9.0% during the first quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock worth $262,000 after buying an additional 284 shares in the last quarter. Parametric Portfolio Associates LLC boosted its holdings in AveXis by 2.9% during the second quarter. Parametric Portfolio Associates LLC now owns 20,943 shares of the company’s stock worth $1,721,000 after buying an additional 598 shares in the last quarter. American International Group Inc. boosted its holdings in AveXis by 26.7% during the first quarter. American International Group Inc. now owns 3,521 shares of the company’s stock worth $268,000 after buying an additional 742 shares in the last quarter. Swiss National Bank boosted its holdings in AveXis by 3.0% during the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock worth $2,083,000 after buying an additional 800 shares in the last quarter. Finally, Seven Bridges Advisors LLC boosted its holdings in AveXis by 49.4% during the second quarter. Seven Bridges Advisors LLC now owns 2,557 shares of the company’s stock worth $210,000 after buying an additional 846 shares in the last quarter. 94.71% of the stock is currently owned by hedge funds and other institutional investors.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.